Lipoprotein
Showing 1 - 25 of 5,508
Hypercholesterolemia, Primary Prevention Trial in Sao Paulo (Phytosterol supplements)
Completed
- Hypercholesterolemia
- Primary Prevention
- Phytosterol supplements
-
Sao Paulo, Other, Brazil
- +1 more
Nov 9, 2023
Elevated Lipoprotein(a) Level, Coronary Artery Disease, Drug-Eluting Stent Trial in Beijing (24 Months DAPT, 12 Months DAPT)
Not yet recruiting
- Elevated Lipoprotein(a) Level
- +3 more
- 24 Months DAPT
- 12 Months DAPT
-
Beijing, Beijing, ChinaFuwai Hospital, National Center for Cardiovascular Diseases, Chi
Aug 26, 2023
Elevated Low-Density Lipoprotein Cholesterol Trial in Herston, Adelaide, Melbourne (SNK-396 - SAD cohort, SNK-396 - MAD Cohort)
Recruiting
- Elevated Low-Density Lipoprotein Cholesterol
- SNK-396 - SAD cohort
- SNK-396 - MAD Cohort
-
Herston, Queensland, Australia
- +2 more
Jun 6, 2023
Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic
Recruiting
- Atherosclerosis
- Aortic Valve Disease
- Thrombotic assessment
- Measurement of Lp(a)
-
Stevenage, United KingdomEast and North Herts NHS Trust
Nov 6, 2023
To Reduce the LDL-C Level in Hypercholesteremia Adult Patients, Combination for Subgroup High LDL-c Patients With Other
Not yet recruiting
- To Reduce the LDL-C Level in Hypercholesteremia Adult Patients
- Combination for Subgroup High LDL-c Patients With Other Comorbidities
- RN0191 INJECTION
- (no location specified)
Jun 14, 2023
Lipoprotein Metabolism in Normal Volunteers and High Levels of
Completed
- Hypolipoproteinemia
- +3 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Cardiovascular Disease Trial in Saint-Denis (blood lipoprotein (a) test)
Recruiting
- Cardiovascular Disease
- blood lipoprotein (a) test
-
Saint-Denis, FranceCentre Hospitalier Universitaire de la Réunion
Aug 29, 2022
Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a) Trial (SLN360, Placebo)
Not yet recruiting
- Cardiovascular Diseases
- +2 more
- SLN360
- Placebo
- (no location specified)
Sep 12, 2022
Primary Hypercholesterolemia or Mixed Dyslipidemia Trial (Inclisiran, Matching Placebo for Inclisiran)
Not yet recruiting
- Primary Hypercholesterolemia or Mixed Dyslipidemia
- Inclisiran
- Matching Placebo for Inclisiran
- (no location specified)
May 24, 2023
Hypercholesterolemia, Familial, Dyslipidemias, Cardiovascular Diseases Trial in Rostock, Dresden (Lipoprotein Apheresis MONET
Completed
- Hypercholesterolemia, Familial
- +2 more
- Lipoprotein Apheresis MONET and DALI
- Lipoprotein Apheresis DIAMED and DALI
-
Rostock, Mecklenburg-Vorpommern, Germany
- +1 more
Jul 27, 2022
Acute Coronary Syndrome, Lipoprotein Disorder, Acute Myocardial Infarction Trial in Caserta
Recruiting
- Acute Coronary Syndrome
- +3 more
-
Caserta, ItalyAORN S. Anna e S. Sebastiano
Aug 9, 2022
OLOMAX for Blood Pressure and Low-density Lipoprotein
Recruiting
- Hypertension
- Dyslipidemias
- Olmesartan Medoxomil/ Amlodipine Besylate/ Rosuvastatin Ca
-
Seoul, Korea, Republic ofSeoul St.Mary's Hospital
Dec 13, 2022
Thrombogenicity of Lipoprotein A: Laboratory Study Defining
Not yet recruiting
- Cardiovascular Disease and Lipid Disorders
- Cardiac Disease
- Non-interventional
-
Middlesbrough, Teesside, United KingdomSouth Tees Hospitals NHS FT
Apr 14, 2022
Lipoprotein Lipase Deficiency, Familial Hyperlipoproteinemia Type 1, Familial Hyperchylomicronemia Trial in Berlin
Active, not recruiting
- Lipoprotein Lipase Deficiency
- +2 more
- Observational study
-
Berlin, GermanyInterdisciplinary Metabolism Center, Lipid Out-Patient-Clinic, L
May 9, 2022
Lymphedema Trial in Nice (lipoprotein (a))
Not yet recruiting
- Lymphedema
- lipoprotein (a)
-
Nice, Centre Antoine Lacassagne, FranceCAUSERET Marion
Jul 19, 2023
Hyperlipoproteinemia(a) Trial (Pelacarsen (TQJ230) 80 mg s.c., Corresponding Placebo)
Not yet recruiting
- Hyperlipoproteinemia(a)
- Pelacarsen (TQJ230) 80 mg s.c.
- Corresponding Placebo
- (no location specified)
Mar 22, 2022
Aortic Stenosis Trial (Pelacarsen (TQJ230) 80mg, Matching )
Not yet recruiting
- Aortic Stenosis
- Pelacarsen (TQJ230) 80mg
- Matching placebo
- (no location specified)
Dec 2, 2022
Elevated Serum Lipoprotein(a) Trial in Hong Kong (Olpasiran)
Completed
- Elevated Serum Lipoprotein(a)
-
Hong Kong, HK, Hong KongQueen Mary Hospital
Mar 30, 2022
High Density Lipoprotein Function in Type 1 Diabetic Nephropathy
Recruiting
- Type 1 Diabetes
- Blood samples
- Urine sample
-
Dijon, FranceChu Dijon Bourogne
Jun 8, 2022
Cardiovascular Diseases Trial in Shatin (TQJ230, Placebo)
Active, not recruiting
- Cardiovascular Diseases
- TQJ230
- Placebo
-
Shatin, Hong KongThe Chinese University of Hong Kong
Sep 16, 2022
Inclisiran Among Early Users in Germany
Completed
- High Levels of Low-density Lipoprotein Cholesterol
-
Basel, SwitzerlandNovartis
May 12, 2023
Coronary Artery Diseasse Trial in Seoul (fixed high potent statin therapy, targeted LDL-C goal statin)
Active, not recruiting
- Coronary Artery Diseasse
- fixed high potent statin therapy
- targeted LDL-C goal statin
-
Seoul, Korea, Republic ofDivision of Cardiology, Department of Internal Medicine, Yonsei
Jul 19, 2022
COVID-19 Stress Syndrome, COVID-19 Vaccine Adverse Reaction, COVID-19-Associated Thromboembolism Trial in Chongqing
Active, not recruiting
- COVID-19 Stress Syndrome
- +5 more
- Atorvastatin Calcium Tablets
-
Chongqing, Chongqing, ChinaResidential Address
May 1, 2023